![](/images/graphics-bg.png)
Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
المؤلفون المشاركون
Huang, Lvzhen
Li, Xiaoxin
Chen, Xiao-Li
Bai, Yu-Jing
Hu, Qin-Rui
Chen, Yi
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-04-09
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Objective.
To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment.
Methods.
This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases.
Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited.
Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome.
Data was collected and analyzed by SPSS 16.0.
Results.
Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment.
Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment.
On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P=0.000).
Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P=0.004).
Conclusions.
The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hu, Qin-Rui& Bai, Yu-Jing& Chen, Xiao-Li& Huang, Lvzhen& Chen, Yi& Li, Xiaoxin. 2017. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology،Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hu, Qin-Rui…[et al.]. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology No. 2017 (2017), pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hu, Qin-Rui& Bai, Yu-Jing& Chen, Xiao-Li& Huang, Lvzhen& Chen, Yi& Li, Xiaoxin. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology. 2017. Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1185012
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)